Beijing SL’s Generic Pomalidomide Approved For Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
A subsidiary of Beijing SL Pharmaceutical, Nanjing Cavendish Bio-engineering Technology, has applied to conduct clinical trials for its Class III new drug, Pomalyst, and was accepted by the China FDA.